We are live on ! Find out more
AAP

Ardsley Advisory Partners Portfolio holdings

AUM $960M
1-Year Est. Return 207.76%
This Fund
S&P 500
This Quarter Est. Return
+62.68%
1 Year Est. Return
+207.76%
3 Year Est. Return
+554.53%
5 Year Est. Return
+728.66%
10 Year Est. Return
+4,084.52%
AUM
$470M
AUM Growth
+$215M
Cap. Flow
+$84.2M
Cap. Flow %
17.91%
Top 10 Hldgs %
50.14%
Holding
180
New
79
Increased
20
Reduced
20
Closed
47

Top Buys

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$19.9M
2
TMUS icon
T-Mobile US
TMUS
+$17.2M
3
ABBV icon
AbbVie
ABBV
+$12.5M
4
LITE icon
Lumentum
LITE
+$11.5M
5
QCOM icon
Qualcomm
QCOM
+$10.1M

Top Sells

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$8.88M
2
FTAI icon
FTAI Aviation
FTAI
+$8.81M
3
STAA icon
STAAR Surgical
STAA
+$8.17M
4
RUN icon
Sunrun
RUN
+$6.51M
5
ZEN
ZENDESK INC
ZEN
+$6.08M

Sector Composition

Rank Sector Weight
1 Technology 23.99%
2 Healthcare 17.02%
3 Consumer Staples 13.31%
4 Industrials 11.19%
5 Consumer Discretionary 7.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UBER icon
101
Uber
UBER
$144B
$311K 0.07%
+10,000
New +$312K
MRK icon
102
Merck
MRK
$326B
$309K 0.07%
4,192
-1,205
-22% -$90.7K
CNR
103
DELISTED
Cornerstone Building Brands, Inc.
CNR
$303K 0.06%
+50,000
New +$255K
IEA
104
DELISTED
Infrastructure and Energy Alternatives, Inc. Common Stock
IEA
$300K 0.06%
+75,000
New +$166K
QTNT
105
DELISTED
Quotient Limited Ordinary Shares
QTNT
$296K 0.06%
1,000
– –
SYNH
106
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$291K 0.06%
+5,000
New +$269K
TPTX
107
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$291K 0.06%
+4,500
New +$260K
ADMA icon
108
ADMA Biologics
ADMA
$2.04B
$285K 0.06%
97,100
+22,500
+30% +$64.6K
QRVO icon
109
Qorvo
QRVO
$8.09B
$276K 0.06%
+2,500
New +$248K
BPMC
110
DELISTED
Blueprint Medicines
BPMC
$273K 0.06%
+3,500
New +$237K
ALDX icon
111
Aldeyra Therapeutics
ALDX
$95.3M
$259K 0.06%
62,100
+25,000
+67% +$91.3K
FATE icon
112
Fate Therapeutics
FATE
$270M
$257K 0.05%
+7,500
New +$224K
GMAB icon
113
Genmab
GMAB
$17.8B
$254K 0.05%
+7,500
New +$204K
SYRE icon
114
Spyre Therapeutics
SYRE
$8.68B
$251K 0.05%
+1,084
New +$206K
QCOM icon
115
PUT
Qualcomm
QCOM
$172B
$228K 0.05%
+2,500
New +$200K
GTM
116
PUT
ZoomInfo Technologies
GTM
$967M
$204K 0.04%
+4,000
New +$191K
VST icon
117
Vistra
VST
$50.1B
$186K 0.04%
+10,000
New +$188K
LAB icon
118
Standard BioTools
LAB
$311M
$160K 0.03%
+40,000
New +$139K
HROW icon
119
Harrow
HROW
$1.47B
$156K 0.03%
30,000
– –
GNMK
120
DELISTED
GenMark Diagnostics, Inc
GNMK
$147K 0.03%
+10,000
New +$102K
ABEO icon
121
Abeona Therapeutics
ABEO
$343M
$146K 0.03%
2,000
+400
+25% +$27.6K
APTO
122
DELISTED
Aptose Biosciences, Inc.
APTO
$125K 0.03%
+44
New +$142K
ERIC icon
123
Ericsson
ERIC
$32.7B
$102K 0.02%
+11,000
New +$95.5K
SEEL
124
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$81K 0.02%
21
+3
+17% +$9.96K
CSTM icon
125
Constellium
CSTM
$3.96B
$77K 0.02%
+10,000
New +$72.7K
3 4
5
6 7

Similar funds

NA
Navellier & Associates Reno, Nevada $960M AUM 79.37% 1-Year Est. Return
MK
MASTERINVEST Kapitalanlage Vienna $962M AUM 27.59% 1-Year Est. Return
QIM
Quantitative Investment Management Charlottesville, Virginia $963M AUM 12.95% 1-Year Est. Return
JVBC
J.V. Bruni & Co Colorado Springs, Colorado $958M AUM 22.2% 1-Year Est. Return
TFP
Triple Frond Partners San Francisco, California $963M AUM 27.45% 1-Year Est. Return
UWPG
Ullmann Wealth Partners Group Jacksonville Beach, Florida $963M AUM 17.06% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
PHS
Pekin Hardy Strauss Chicago, Illinois $957M AUM 44.61% 1-Year Est. Return

Ardsley Advisory Partners's Q2 2020 Portfolio in Review

As of Q2 2020, Ardsley Advisory Partners held 180 positions worth $470M, up 84% from $255M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Ardsley Advisory Partners deployed $84.2M of net new capital in Q2 2020, opening 79 new positions and adding to 20 existing holdings. Its largest new stake was T-Mobile US: 179,510 shares worth $18.7M.

By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 21% a quarter earlier, followed by Healthcare and Consumer Staples.

On the sell side, the largest reduction was State Street SPDR S&P Biotech ETF, an estimated $8.88M trimmed.

  • Ardsley Advisory Partners's largest Q2 2020 buy was T-Mobile US: 179,510 shares worth $18.7M.
  • Ardsley Advisory Partners added most to Microsoft in Q2 2020, an estimated $19.9M increase.
  • Ardsley Advisory Partners's biggest Q2 2020 reduction was State Street SPDR S&P Biotech ETF, cutting an estimated $8.88M.
  • Ardsley Advisory Partners fully exited ZENDESK INC in Q2 2020, selling an estimated $6.08M.
  • Ardsley Advisory Partners's ten largest holdings make up 50% of its $470M portfolio in Q2 2020.
  • Ardsley Advisory Partners opened 79 new positions and closed 47 in Q2 2020.
  • Ardsley Advisory Partners's portfolio value rose 84% quarter-over-quarter to $470M.

Based on Ardsley Advisory Partners's 13F filing for Q2 2020, filed 14 Aug 2020.